| Variable . | Single-chamber ( n = 111) . | Dual-chamber ( n = 112) . |
|---|---|---|
| Atrial fibrillation | 19 (17%) | 26 (23%) |
| Congestive heart failure | 22 (20%) | 26 (23%) |
| NYHA I | 39 (35%) | 33 (29%) |
| NYHA II | 64 (58%) | 67 (60%) |
| NYHA III | 8 (7%) | 11 (10%) |
| NYHA IV | 0 (0%) | 1 (1%) |
| Coronary artery disease | 88 (80%) | 98 (87%) |
| Recent MI (<3 months) | 18 (20%) | 12 (2%) |
| Old MI (>3 months) | 58 (66%) | 78 (80%) |
| Angina | 23 (26%) | 25 (25%) |
| Prior PTCA | 26 (30%) | 25 (25%) |
| Prior CABG | 33 (37%) | 34 (35%) |
| Cardiomyopathy | 51 (46%) | 46 (41%) |
| Dilated | 31/51 (61%) | 30/46 (65%) |
| Hypertrophic | 2/51 (4%) | 4/46 (9%) |
| Other | 18/51 (35%) | 12/46 (26%) |
| Valvular heart disease | 19 (17%) | 11 (10%) |
| Hypertension | 64 (58%) | 54 (48%) |
| Congenital heart disease | 1 (0.9%) | 0 (0%) |
| Cerebrovascular disease | 11 (10%) | 14 (12%) |
| Peripheral vascular disease | 12 (11%) | 13 (12%) |
| Primary prevention ICD indication | ||
| Secondary prevention ICD indication | ||
| Class III antiarrhythmic drugs | 29 (26%) | 30 (27%) |
| Class IC antiarrhythmic drugs | 1 (1%) | 0 |
| Beta blockers | 55 (50%) | 50 (45%) |
| Anticoagulation agents | 20 (18%) | 20 (18%) |
| Antiplatelet agents | 62 (56%) | 60 (54%) |
| ACE-inhibitors | 69 (62%) | 62 (55%) |
| Variable . | Single-chamber ( n = 111) . | Dual-chamber ( n = 112) . |
|---|---|---|
| Atrial fibrillation | 19 (17%) | 26 (23%) |
| Congestive heart failure | 22 (20%) | 26 (23%) |
| NYHA I | 39 (35%) | 33 (29%) |
| NYHA II | 64 (58%) | 67 (60%) |
| NYHA III | 8 (7%) | 11 (10%) |
| NYHA IV | 0 (0%) | 1 (1%) |
| Coronary artery disease | 88 (80%) | 98 (87%) |
| Recent MI (<3 months) | 18 (20%) | 12 (2%) |
| Old MI (>3 months) | 58 (66%) | 78 (80%) |
| Angina | 23 (26%) | 25 (25%) |
| Prior PTCA | 26 (30%) | 25 (25%) |
| Prior CABG | 33 (37%) | 34 (35%) |
| Cardiomyopathy | 51 (46%) | 46 (41%) |
| Dilated | 31/51 (61%) | 30/46 (65%) |
| Hypertrophic | 2/51 (4%) | 4/46 (9%) |
| Other | 18/51 (35%) | 12/46 (26%) |
| Valvular heart disease | 19 (17%) | 11 (10%) |
| Hypertension | 64 (58%) | 54 (48%) |
| Congenital heart disease | 1 (0.9%) | 0 (0%) |
| Cerebrovascular disease | 11 (10%) | 14 (12%) |
| Peripheral vascular disease | 12 (11%) | 13 (12%) |
| Primary prevention ICD indication | ||
| Secondary prevention ICD indication | ||
| Class III antiarrhythmic drugs | 29 (26%) | 30 (27%) |
| Class IC antiarrhythmic drugs | 1 (1%) | 0 |
| Beta blockers | 55 (50%) | 50 (45%) |
| Anticoagulation agents | 20 (18%) | 20 (18%) |
| Antiplatelet agents | 62 (56%) | 60 (54%) |
| ACE-inhibitors | 69 (62%) | 62 (55%) |
| Variable . | Single-chamber ( n = 111) . | Dual-chamber ( n = 112) . |
|---|---|---|
| Atrial fibrillation | 19 (17%) | 26 (23%) |
| Congestive heart failure | 22 (20%) | 26 (23%) |
| NYHA I | 39 (35%) | 33 (29%) |
| NYHA II | 64 (58%) | 67 (60%) |
| NYHA III | 8 (7%) | 11 (10%) |
| NYHA IV | 0 (0%) | 1 (1%) |
| Coronary artery disease | 88 (80%) | 98 (87%) |
| Recent MI (<3 months) | 18 (20%) | 12 (2%) |
| Old MI (>3 months) | 58 (66%) | 78 (80%) |
| Angina | 23 (26%) | 25 (25%) |
| Prior PTCA | 26 (30%) | 25 (25%) |
| Prior CABG | 33 (37%) | 34 (35%) |
| Cardiomyopathy | 51 (46%) | 46 (41%) |
| Dilated | 31/51 (61%) | 30/46 (65%) |
| Hypertrophic | 2/51 (4%) | 4/46 (9%) |
| Other | 18/51 (35%) | 12/46 (26%) |
| Valvular heart disease | 19 (17%) | 11 (10%) |
| Hypertension | 64 (58%) | 54 (48%) |
| Congenital heart disease | 1 (0.9%) | 0 (0%) |
| Cerebrovascular disease | 11 (10%) | 14 (12%) |
| Peripheral vascular disease | 12 (11%) | 13 (12%) |
| Primary prevention ICD indication | ||
| Secondary prevention ICD indication | ||
| Class III antiarrhythmic drugs | 29 (26%) | 30 (27%) |
| Class IC antiarrhythmic drugs | 1 (1%) | 0 |
| Beta blockers | 55 (50%) | 50 (45%) |
| Anticoagulation agents | 20 (18%) | 20 (18%) |
| Antiplatelet agents | 62 (56%) | 60 (54%) |
| ACE-inhibitors | 69 (62%) | 62 (55%) |
| Variable . | Single-chamber ( n = 111) . | Dual-chamber ( n = 112) . |
|---|---|---|
| Atrial fibrillation | 19 (17%) | 26 (23%) |
| Congestive heart failure | 22 (20%) | 26 (23%) |
| NYHA I | 39 (35%) | 33 (29%) |
| NYHA II | 64 (58%) | 67 (60%) |
| NYHA III | 8 (7%) | 11 (10%) |
| NYHA IV | 0 (0%) | 1 (1%) |
| Coronary artery disease | 88 (80%) | 98 (87%) |
| Recent MI (<3 months) | 18 (20%) | 12 (2%) |
| Old MI (>3 months) | 58 (66%) | 78 (80%) |
| Angina | 23 (26%) | 25 (25%) |
| Prior PTCA | 26 (30%) | 25 (25%) |
| Prior CABG | 33 (37%) | 34 (35%) |
| Cardiomyopathy | 51 (46%) | 46 (41%) |
| Dilated | 31/51 (61%) | 30/46 (65%) |
| Hypertrophic | 2/51 (4%) | 4/46 (9%) |
| Other | 18/51 (35%) | 12/46 (26%) |
| Valvular heart disease | 19 (17%) | 11 (10%) |
| Hypertension | 64 (58%) | 54 (48%) |
| Congenital heart disease | 1 (0.9%) | 0 (0%) |
| Cerebrovascular disease | 11 (10%) | 14 (12%) |
| Peripheral vascular disease | 12 (11%) | 13 (12%) |
| Primary prevention ICD indication | ||
| Secondary prevention ICD indication | ||
| Class III antiarrhythmic drugs | 29 (26%) | 30 (27%) |
| Class IC antiarrhythmic drugs | 1 (1%) | 0 |
| Beta blockers | 55 (50%) | 50 (45%) |
| Anticoagulation agents | 20 (18%) | 20 (18%) |
| Antiplatelet agents | 62 (56%) | 60 (54%) |
| ACE-inhibitors | 69 (62%) | 62 (55%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
